Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Mental illness is often chronic, severe, and difficult to treat. Though there has been significant progress towards establishing effective and efficient interventions for psychological health problems, many individuals do not gain lasting benefits from these treatments. The Memory Support Intervention (MSI) was developed utilizing existing findings from the cognitive science literature to improve treatment outcomes. In this study, the investigators aim to conduct an open trial that includes individuals 55 years and older to assess if a simplified version of the Memory Support Intervention improves sleep and circadian functioning, reduces functional impairment, and improves patient memory for treatment.
Given the huge burden associated with mental illness, a major challenge ahead is to hasten progress toward developing and testing highly efficient and effective interventions for psychological health problems. Progress toward establishing evidence-based psychosocial treatments for most types of mental illness has been excellent, particularly the cognitive and behavioral treatments (CBT). However, much work remains. The effect sizes are moderate, gains may not persist, and there are patients who derive little or no benefit. Even under optimal conditions, treatment failure is too common. Hence, the challenge is to improve outcomes. Seminal progress toward meeting this challenge must include innovations that are safe, powerful, inexpensive and simple (for fast and effective dissemination).
The proposed research seeks to extend the investigators' program of research on one such innovation. With an R34 and an R01 from NIMH, the investigators have been seeking to improve outcome by improving memory for the content of therapy sessions. To achieve this goal, the investigators have developed and adapted existing findings from the education and cognitive science literatures. The resulting Memory Support Intervention (MSI) involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory.
This line of research arises from several lines of evidence: (a) memory for the content of therapy sessions is poor and (b) memory impairment is modifiable. Although the outcomes will be relevant to psychosocial treatments for a broad range of problems, the focus of this proposal is one treatment for sleep and circadian dysfunction because (a) sleep problems are one of the most prevalent psychological health problems, (b) there is substantial and promising evidence for the efficacy of the transdiagnostic sleep and circadian (TranS-C), yet there is also room for improvement in outcome and (c) sleep problems are associated with memory impairment.
This pilot study will be conducted in order to collect data on individuals who are 55 years and older because memory functioning can decline over this phase of the lifespan. Sleep and circadian problems are also common.
The aim is: To conduct an open trial that includes n = 40 individuals 55 years and older to assess if the Memory Support Intervention (a) improves sleep and circadian functioning, (b) reduces functional impairment and (c) improves patient memory for treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Memory Support Intervention | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Trans-C for sleep and circadian function + Memory Support | Behavioral | The Memory Support Intervention will be delivered interwoven with Trans-C. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Patient-level outcome: Patient-Reported Outcomes Measurement Information System - Sleep Disturbance | Assesses perceived functional impairments related to sleep problems using a self-report questionnaire. The minimum value is 8. The maximum value is 40. Higher scores mean more sleep disturbance (worse outcome). | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Sheehan Disability Scale | Assesses functional impairment on a scale from 0 to 30, where higher scores mean higher impairment | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Positive and Negative Affect Scale | Positive affect scores can range from 10-15, with higher scores representing higher levels of positive affect. Negative affect scores can range from 10-50, with lower scores representing lower levels of negative affect | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| STOP-BANG Questionnaire | Scores range from 0-8 with higher scores associated with higher risk of experiencing sleep apnea | Baseline only |
| Screen for periodic limb movement disorder | Restless Leg Syndrome Questions |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Allison Harvey, PhD | University of California, Berkeley | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, Berkeley | Berkeley | California | 94720-1650 | United States |
Not provided
| ID | Term |
|---|---|
| D012893 | Sleep Wake Disorders |
| D021081 | Chronobiology Disorders |
| ID | Term |
|---|---|
| D009422 | Nervous System Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D012890 | Sleep |
| ID | Term |
|---|---|
| D009424 | Nervous System Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Perceived Stress Scale | Individual scores on the Perceived Stress Scale can range from 0-40 with higher scores indicating higher perceived stress | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Satisfaction with Life Scale | 5-item instrument designed to measure global cognitive judgements of satisfaction with one's life. Scores can range from 5-35 with higher scores indicating higher levels of satisfaction with life. | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Credibility Expectancy Questionnaire | Measures the credibility and expectation of improvement from the treatment. Scores can range from 9- 81 with higher scores indicating higher treatment satisfaction. | At treatment Week 2 and at post-treatment which is 8-10 weeks after the beginning of treatment |
| Means and Variability of sleep efficiency (Daily Sleep Diary) | Daily Sleep Diary means and variability for sleep efficiency (total sleep time/time in bed X 100), Total sleep time (TST), Total wake time (TWT), bedtime, waketime. | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Patient-Reported Outcomes Measurement Information System - Sleep Related Impairment | Assesses perceived functional impairments related to sleep problems in a self-report questionnaire. The minimum value is 16. The maximum value is 80. Higher scores mean more sleep related problems (worse outcome). | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Composite Sleep Health Score | Composite Sleep Health Score which is defined as the sum of scores on 6 sleep health dimensions: Regularity (Midpoint fluctuation), Satisfaction (Sleep quality question on PROMIS-SD), Alertness (Daytime sleepiness question on PROMIS-SRI), Timing (Mean midpoint), Efficiency (Sleep efficiency) and Duration (Total Sleep Time). | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| British Columbia Complaints Inventory | Assessed perceived cognitive difficulties, scale consists of 6 items. Scores can range from 0-18 with higher scores indicating higher levels of perceived cognitive difficulties | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Mutlidimensional Fatigue Inventory | 20-item scale designed to evaluate five dimensions of fatigue. Scores can range from 20-100 with higher total scores corresponding with more acute levels of fatigue | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Cognitive Failures Questionnaire | Used to assess the frequency with which people experienced cognitive failures. Scores range from 0-100, with higher scores indicating higher levels of cognitive failures. | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Epworth Sleepiness Scale | Used to assess daytime sleepiness. Scores can range from 0-24 with higher scores indicating higher levels of daytime sleepiness. | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Memory for Treatment | Recall on the Patient Treatment Recall Task | At post-treatment, which is 8-10 weeks after the beginning of treatment |
| Generalization Task Questionnaire | Measures how treatment gains sustained during therapy have generalized to the participant's thinking and functioning during every day life | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Acceptability Intervention Measure | Assess provider perceptions of the appropriateness of the treatment intervention using a self-report questionnaire | Through therapy completion, an average of 8 weeks |
| Intervention Appropriateness Measure | Assesses provider perceptions of the appropriateness of the treatment intervention using a self-report questionnaire | Through therapy completion, an average of 8 weeks |
| Feasibility of Intervention Measure | Assesses provider perceptions of the feasibility of the intervention using a self-report questionnaire | Through therapy completion, an average of 8 weeks |
| Baseline only |
| Medication Dosage | Collect dose, type, frequency and changes in medications | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Medication Type | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Medication Use Frequency | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Change in Medications | Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment |
| Semi-structured interview | Assess patient perceptions of treatment | Only at post-treatment which is 8-10 weeks after the beginning of treatment |
| D001523 | Mental Disorders |